Researchers point to several reasons for this variation, including differences between specific GLP-1 medications, individual mental health history, the presence of eating disorders or mood disorders, and differences in dosage, duration of use, and overall health
[8] [9] The Risks of Obtaining Retatrutide Outside Clinical Trials Sourcing retatrutide outside clinical trials risks counterfeit or contaminated products, an incompletely established adverse effect profile, no medical oversight, and potential legal consequences under UK medicines law
For eligible dialysis patients, GLP-1 RAs like Ozempic can offer several potential benefits, including significant body weight loss, improved glycemic control for those with type 2 diabetes, and a reduction in interdialytic weight gain
Doses ranging from 0.25 mg to 1.0 mg daily have been investigated